Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15.
about
The role of c-kit and imatinib mesylate in uveal melanoma.Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapyMetastatic disease from uveal melanoma: treatment options and future prospectsAnimal Models of Uveal Melanoma: Methods, Applicability, and LimitationsRecent developments in prognostic and predictive testing in uveal melanomaMicrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implicationsMetastatic uveal melanoma: biology and emerging treatmentsUveal melanoma cells utilize a novel route for transendothelial migrationEffect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.Delayed systemic recurrence of uveal melanomaSignificance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastasesTreatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells.ZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression.Role of Epigenetics in Uveal MelanomaInhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases.Visual Loss from Choroidal Melanoma Mimicking Neurological Syndromes.Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasisYttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.GDF-15: a novel serum marker for metastases in uveal melanoma patients.Repression of genes involved in melanocyte differentiation in uveal melanoma.GNAQ mutation in a patient with metastatic mucosal melanoma.Primary mucosal melanomas: a comprehensive review.Ocular melanoma: an overview of the current status.Current and emerging treatment options for uveal melanoma.Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses.Overexpression of high mobility group A1 protein in human uveal melanomas: implication for prognosis.Genomic, prognostic, and cell-signaling advances in uveal melanoma.Whole body PET/CT for initial staging of choroidal melanoma.Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture.A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma.Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations.Choroidal melanomaLong-term survivors with metastatic uveal melanoma.Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeRecent trends and future perspectives in isolated hepatic perfusion in the treatment of liver tumors.Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma CellsMalignant melanoma and bone resorption.
P2860
Q21245647-824EA1AC-5AB0-47F6-B1D2-9D6A86AA694AQ24670470-AA46E292-EC26-4E56-9032-98D99C927E7CQ26738377-AA63CA78-8082-49E7-9A76-84333E20BD63Q26745595-0DA98277-1AC2-469E-8F0F-33161CAD28F3Q26824096-4B7AC680-D765-4055-829B-89312264328AQ26996059-8735346F-F123-4B57-89CD-4894FA6BFCB0Q27028063-11B4C921-03FA-48DD-A0A5-7F01757D0D99Q27319660-28E3DB58-93C1-4346-8097-4AB1C51CE229Q27853021-DC20FE8D-0BFE-4D19-B51C-F24E9493BF82Q28268997-F5FE8FFB-EB7A-4A3C-9745-BB12D80A116EQ28294875-1056D01D-5BD6-4340-B31D-E3F955C875CEQ33440852-37878F17-2099-4974-92B4-3E221B1275ECQ33631459-595523E9-2A4B-4E68-BEC8-39BD187799CFQ33671316-FF413909-7A7A-4969-9F46-515D56E7DAA1Q33703270-E691EA7B-E67C-4C7C-ADBE-86E768089664Q33740330-C9026630-93E5-4489-88E3-8CE2ED30109AQ33782173-02B57A9D-7602-48E5-970A-A036049E5BF6Q33827461-2B824EBF-A967-4B40-9D0B-6FF22A804C2BQ33911553-75E1DD7B-6C19-40F2-9E11-5ADCCE23A67CQ34007029-16BF2759-2915-48B3-BED8-9DC09D7F79D2Q34344533-615A7CD0-96DF-4218-BB1E-0F30B3D83C57Q34467908-3A97DBD9-DF43-467C-AAF3-126C99886DF9Q34644082-B244A24A-A900-427C-AC67-CBD363C428DAQ34653896-D9925504-4641-4B2F-AD11-F39520080398Q34655878-53F119A7-F29E-413D-A212-26121DD215E3Q34660509-EF12A87A-EF51-4D76-8521-394FA9BB27DAQ34671157-F33EDE9A-EBA9-4619-8022-362F4945A8BEQ34918493-3DC3C27F-C6DE-4EBC-B945-A6F8869B18B2Q35163192-784BDE10-6F93-4F11-A6DD-90E5C12A5851Q35593819-04EA7B40-581B-48AE-86B0-502E23388535Q35755594-F451D4AC-4249-4A87-B54A-09A1F2A76CD7Q35823432-97B34CDF-E88E-4A69-B284-EE2C0154199DQ35904981-5856092C-7FD4-48C8-B3AA-62E7E88D0D89Q35920809-4CCB042B-A50A-4F9F-8E46-81AE94709838Q36088202-BA69242B-2DFE-428A-AD52-13646A392F94Q36265620-ACE8342E-ED99-41B6-B169-2765E9DF53FBQ36448687-84FFE688-061C-420D-AE70-824B19C10541Q36468749-E29E6CFF-9A35-42BD-9948-5644724F7520Q36540937-F81AD411-764D-4040-B4A2-CBE2F3F24D03Q36614173-4E922ADD-BAC4-4215-A88F-E00A1C2BD728
P2860
Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Assessment of metastatic disea ...... dy (COMS): COMS report no. 15.
@ast
Assessment of metastatic disea ...... dy (COMS): COMS report no. 15.
@en
Assessment of metastatic disea ...... borative Ocular Melanoma Study
@nl
type
label
Assessment of metastatic disea ...... dy (COMS): COMS report no. 15.
@ast
Assessment of metastatic disea ...... dy (COMS): COMS report no. 15.
@en
Assessment of metastatic disea ...... borative Ocular Melanoma Study
@nl
prefLabel
Assessment of metastatic disea ...... dy (COMS): COMS report no. 15.
@ast
Assessment of metastatic disea ...... dy (COMS): COMS report no. 15.
@en
Assessment of metastatic disea ...... borative Ocular Melanoma Study
@nl
P1433
P1476
Assessment of metastatic disea ...... dy (COMS): COMS report no. 15.
@en
P2093
Collaborative Ocular Melanoma Study Group.
P304
P356
10.1001/ARCHOPHT.119.5.670
P407
P577
2001-05-01T00:00:00Z